Literature DB >> 32710484

Characterization of individuals with selected muscular dystrophies from the expanded pilot of the Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) in the United States.

Bailey Wallace1,2, K Tiffany Smith2,3, Shiny Thomas4, Kristin M Conway5, Christina Westfield6, Jennifer G Andrews6, Richard O Weinert7, Thuy Quynh N Do2,8, Natalie Street2.   

Abstract

INTRODUCTION: Data on muscular dystrophies (MDs), a heterogeneous group of heritable diseases hallmarked by progressive muscle deterioration, are scarce.
OBJECTIVE: We describe cross-sectional sociodemographic and clinical characteristics of individuals with congenital, distal, Emery-Dreifuss, facioscapulohumeral, limb-girdle, myotonic, or oculopharyngeal MD.
METHODS: The study was conducted in four sites (Arizona, Colorado, Iowa, and 12 western New York counties) as a pilot expansion of the Muscular Dystrophy Surveillance, Tracking and Research Network, funded by the Centers for Disease Control and Prevention. MDs were detected in healthcare facilities and administrative data sources using International Classification of Disease codes. Our sample contains 1,723 individuals with a MD diagnosis and a healthcare encounter between January 1, 2007 and December 31, 2011. RESULTS AND
CONCLUSIONS: Individuals were mostly non-Hispanic and white. Median ages ranged from 9.2 to 66.0 years. Most (98%) had health insurance. The proportion of individuals who were disabled or unable to work increased with age (range: 8.6-46.4%). People with limb-girdle MD aged ≥18 years were more likely to be nonambulatory (range: 24.5-44.7%). The percentages of individuals with documented clinical interventions during the surveillance period were low. The most common cause of death was respiratory causes (46.3-57.1%); an ICD-10 code for MD (G71.1 or G71.0) was reported for nearly one-half. Our findings show wide variability in sociodemographic and clinical characteristics across MDs.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  MD STARnet; epidemiology; muscular dystrophy; population-based; surveillance

Mesh:

Year:  2020        PMID: 32710484      PMCID: PMC8114775          DOI: 10.1002/bdr2.1764

Source DB:  PubMed          Journal:  Birth Defects Res            Impact factor:   2.661


  29 in total

1.  Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Authors:  Peter B Kang; Leslie Morrison; Susan T Iannaccone; Robert J Graham; Carsten G Bönnemann; Anne Rutkowski; Joseph Hornyak; Ching H Wang; Kathryn North; Maryam Oskoui; Thomas S D Getchius; Julie A Cox; Erin E Hagen; Gary Gronseth; Robert C Griggs
Journal:  Neurology       Date:  2015-03-31       Impact factor: 9.910

2.  If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).

Authors:  James E Hilbert; John T Kissel; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Donald B Sanders; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  Contemp Clin Trials       Date:  2011-11-26       Impact factor: 2.226

3.  Prevalence and clinical correlates of sleep disordered breathing in myotonic dystrophy types 1 and 2.

Authors:  Maria Laura Ester Bianchi; Anna Losurdo; Chiara Di Blasi; Massimo Santoro; Marcella Masciullo; Giulia Conte; Venanzio Valenza; Antonello Damiani; Giacomo Della Marca; Gabriella Silvestri
Journal:  Sleep Breath       Date:  2013-12-06       Impact factor: 2.816

4.  The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology.

Authors:  Lisa A Miller; Paul A Romitti; Christopher Cunniff; Charlotte Druschel; Katherine D Mathews; F John Meaney; Dennis Matthews; Jiji Kantamneni; Zhen-Fang Feng; Nancy Zemblidge; Timothy M Miller; Jennifer Andrews; Deborah Fox; Emma Ciafaloni; Shree Pandya; April Montgomery; Aileen Kenneson
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-11

5.  Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices.

Authors:  Valérie Laurent; Sybille Pellieux; Philippe Corcia; Pascal Magro; Bertrand Pierre; Laurent Fauchier; Martine Raynaud; Dominique Babuty
Journal:  Int J Cardiol       Date:  2010-03-12       Impact factor: 4.164

6.  Cochlear function in facioscapulohumeral muscular dystrophy.

Authors:  Dimitrios G Balatsouras; Stavros Korres; Panayota Manta; Angeliki Panousopoulou; Dimitrios Vassilopoulos
Journal:  Otol Neurotol       Date:  2007-01       Impact factor: 2.311

7.  Importance and challenge of making an early diagnosis in LMNA-related muscular dystrophy.

Authors:  M P Menezes; L B Waddell; F J Evesson; S Cooper; R Webster; K Jones; D Mowat; M C Kiernan; H M Johnston; A Corbett; M Harbord; K N North; N F Clarke
Journal:  Neurology       Date:  2012-04-04       Impact factor: 9.910

8.  Muscular Dystrophy Surveillance, Tracking, and Research Network pilot: Population-based surveillance of major muscular dystrophies at four U.S. sites, 2007-2011.

Authors:  ThuyQuynh N Do; Natalie Street; Jennifer Donnelly; Melissa M Adams; Christopher Cunniff; Deborah J Fox; Richard O Weinert; Joyce Oleszek; Paul A Romitti; Christina P Westfield; Julie Bolen
Journal:  Birth Defects Res       Date:  2018-08-02       Impact factor: 2.344

9.  Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Authors:  Rabi Tawil; John T Kissel; Chad Heatwole; Shree Pandya; Gary Gronseth; Michael Benatar
Journal:  Neurology       Date:  2015-07-28       Impact factor: 9.910

Review 10.  Consensus-based care recommendations for adults with myotonic dystrophy type 1.

Authors:  Tetsuo Ashizawa; Cynthia Gagnon; William J Groh; Laurie Gutmann; Nicholas E Johnson; Giovanni Meola; Richard Moxley; Shree Pandya; Mark T Rogers; Ericka Simpson; Nathalie Angeard; Guillaume Bassez; Kiera N Berggren; Deepak Bhakta; Marco Bozzali; Ann Broderick; Janice L B Byrne; Craig Campbell; Edith Cup; John W Day; Elisa De Mattia; Denis Duboc; Tina Duong; Katy Eichinger; Anne-Berit Ekstrom; Baziel van Engelen; Belen Esparis; Bruno Eymard; Marla Ferschl; Shahinaz M Gadalla; Benjamin Gallais; Todd Goodglick; Chad Heatwole; James Hilbert; Venessa Holland; Marie Kierkegaard; Wilma J Koopman; Kari Lane; Daphne Maas; Ami Mankodi; Katherine D Mathews; Darren G Monckton; David Moser; Saman Nazarian; Linda Nguyen; Peg Nopoulos; Richard Petty; Janel Phetteplace; Jack Puymirat; Subha Raman; Louis Richer; Elisabetta Roma; Jacinda Sampson; Valeria Sansone; Benedikt Schoser; Laurie Sterling; Jeffrey Statland; S H Subramony; Cuixia Tian; Careniña Trujillo; Gordon Tomaselli; Chris Turner; Shannon Venance; Aparajitha Verma; Molly White; Stefan Winblad
Journal:  Neurol Clin Pract       Date:  2018-12
View more
  1 in total

1.  Characteristics of Clinical Trial Participants with Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

Authors:  Katherine D Mathews; Kristin M Conway; Amber M Gedlinske; Nicholas Johnson; Natalie Street; Russell J Butterfield; Man Hung; Emma Ciafaloni; Paul A Romitti
Journal:  Children (Basel)       Date:  2021-09-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.